Renuka Iyer, a neuroendocrine tumor expert and Chief of GI Oncology at Roswell Park, discusses the importance of expert pathology reviews and accurate NET classification. Shagufta Shaheen, a GI medical oncologist at Stanford, highlights the management of mixed neuroendocrine neoplasms and therapy-driven dedifferentiation. Aman Chauhan, Director of the Neuroendocrine Tumor Program in Miami, shares insights on novel therapies, including DLL3-targeted strategies and CAR-T early trials, revealing exciting advances in the treatment landscape.
